Receive The Newest Study Notifications

- Pivotal Phase 3 clinical trial reinforced efficacy, safety and tolerability of ubrogepant, an orally-administered CGRP receptor antagonist (gepant) -- -- Acute treatment of migraine with ubrogepant compared with placebo led to significantly greater rates of pain...

- Robust enrollment, with 27 total patients enrolled in the Phase 1 dose escalation portion, including 12 patients in MUM DLT cohorts, 14 patients in MUM overflow cohort, and 1 GNA11 cutaneous melanoma patient in non-MUM GNAQ/11 cohort - All 12 patients in DLT cohorts...

Partnering with Altoida, Inc. to Leverage Predictive Digital Biomarkers for Detection of Mild Cognitive Impairment due to Alzheimer’s Disease Hope Biosciences, a clinical stage biotechnology company focused on developing cell-based therapeutics for acute and chronic...

The Trial will be conducted in the National Cancer Center Hospital of the National Cancer Center Japan. Image credit- shuttershock.com Cancer Intelligence Care Systems, Inc. (CICS) and STELLA PHARMA CORPORATION will commence a Phase I clinical trial of Boron Neutron...

It was a busy week for clinical trial announcements. Here’s a look. ASLAN Pharmaceuticals announced topline data from its TreeTopp (TREatmEnT OPPortunity with varlitinib in biliary tract cancer) trial in second-line biliary tract cancer (BTC). The drug failed to meet...

- Update on Phase 1 Dose-Escalation portion of ongoing Phase 1/2 clinical trial, with specific focus on dosing schema, patient enrollment, and safety data, to be presented at SMR on November 20, 2019 - Phase 2 dose selection and expansion into Phase 2 portion of the...

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--The Bristol-Myers Squibb-Pfizer Alliance today announced the initiation of a new randomized, controlled study, GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals). The...

- The Phase 3 BE READY study, evaluating the efficacy and safety of bimekizumab versus placebo in adults with moderate-to-severe chronic plaque psoriasis, met all primary and ranked secondary endpoints(1) - UCB plans to submit applications to regulatory authorities...

Zealand Pharma completes Phase 3 clinical program for HypoPal® rescue pen, initiates a new Phase 2 clinical proof of concept trial with dasiglucagon, and secures DKK 560 million in additional investment 2019 Q3 Interim Report Copenhagen, November 14, 2019 – Zealand...

- Company stops further development of clinically symptomatic respiratory illness indication but continues development of RTB101 in other aging-related diseases, including Parkinson’s disease -- -- Company remains well funded with $117.3 million in cash, cash...

A new University of Hawaiʻi Cancer Center coordinated liver cancer clinical trial opened in Hawaiʻi combining two different immunotherapy medications to combat the aggressive disease. The Phase II clinical trial is only available in Hawaiʻi, a state with one of the...

Seven Compelling Stories Spotlight the Benefits of Clinical Trial Participation, Access to Life-Saving Medical Advances, and Optimal Lung Cancer Care and Treatment Options WASHINGTON, Nov. 14, 2019 /PRNewswire/ -- LUNGevity, the nation's leading lung cancer-focused...

Topline results expected before the end of Q1/2020 REHOVOT, Israel and NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and...

- Reflects company values and commitment to patients living with hypoparathyroidism - - Top-line data from expanded PaTH Forward Trial expected in first quarter of 2020 - - Company expects to exceed targeted enrollment of 40 subjects - COPENHAGEN, Denmark, Nov. 14,...

 PDC-1421 high-dose data meets primary endpoint on MADRS scale in ITT clinical trial population PDC-1421 low-dose and PDC-1421 high-dose each proved safe, were well-tolerated, and had no serious adverse events associated with them in Phase II clinical trial Company is...

SHANGHAI, Nov. 14, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical-stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune...

A Phase 2b/3 clinical trial of livoletide, a treatment candidate for excessive eating in people with Prader-Willi syndrome (PWS), has completed recruitment of participants who are 8 to 65 years old. However, enrollment of patients from 4 to 7 years old is still...

There are numerous steps involved in the clinical trial recruitment process, many of which begin prior to the official "start". From the planning stages to the conclusion of each trial, the work that must be done is nothing short of extensive. Despite the intensity of...

Huntington Study Group Announces Initiation of Phase III Clinical Study of Valbenazine for the Treatment of Chorea Associated with Huntington Disease. Rochester, NY, November 14, 2019 --(PR.com)-- The Huntington Study Group (HSG), a world leader in spearheading...

VBI Vaccines (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, and Brii Biosciences (“Brii Bio”), a clinical-stage company committed to serving patients’ needs and improving...